Changes in gait variability with anti-dementia drugs: A systematic review and meta-analysis

CNS Drugs

Volumn 28, Issue 6, 2014, Pages 513-518

  Beauchet, O ^a   Launay, C P ^a   Allali, G ^b   Annweiler, C ^a,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; FOLLOW UP; GAIT; GAIT APRAXIA; GAIT DISORDER; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NEUROLOGIC GAIT DISORDER; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; STEADY STATE; STRIDE TIME VARIABILITY; SYSTEMATIC REVIEW; TIME; WALKING; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; GAIT; GALANTAMINE; HUMANS; INDANS; MEMANTINE; NOOTROPIC AGENTS; PIPERIDINES;

EID: 84903817781     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0170-6     Document Type: Review

References (22)

1. Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012;60:2127-36.
2. Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F. Gait analysis in demented subjects: interests and perspectives. Neuropsychiatr Dis Treat. 2008;4:155-60. (Pubitemid 351460986)
3. Allan LM, Ballard CG, Burn DJ, Kenny RA. Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. J Am Geriatr Soc. 2005;53:1681-7. (Pubitemid 43109930)
4. Beauchet O, Allali G, Annweiler C, Bridenbaugh S, Assal F, Kressig RW, Herrmann FR. Gait variability among healthy adults: low and high stride-to-stride variability are both a reflection of gait stability. Gerontology. 2009;55:702-6.
5. Allali G, Kressig RW, Assal F, Herrmann FR, Dubost V, Beauchet O. Changes in gait while backward counting in demented older adults with frontal lobe dysfunction. Gait Posture. 2007;26:572-6. (Pubitemid 47422404)
6. Beauchet O, Allali G, Launay C, Herrmann FR, Annweiler C. Gait variability at fast-pace walking speed: a biomarker of mild cognitive impairment? J Nutr Health Aging. 2013;17:235-9.
7. Hausdorff JM, Rios DA, Eldelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil. 2001;82:1050-6. (Pubitemid 32744331)
8. Maki BE. Gait changes in older adults: predictors of falls or indicators of fear? J Am Geriatr Soc. 1997;45:313-20. (Pubitemid 27114304)
9. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:946-7. (Pubitemid 351652394)
10. Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc. 2009;57:359-60.
11. Beauchet O, Allali G, Launay C, Fantino B, Annweiler C. Does memantine improve the gait of individuals with Alzheimer's disease? J Am Geriatr Soc. 2011;59:2181-2.
12. Beauchet O, Launay C, Allali G, Watfa G, Gallouj K, Herrmann F, Annweiler C. Anti-dementia drugs and changes in gait: a prepost quasi-experimental pilot study. BMC Neurol. 2013;13:184.
13. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol. 2009;9:42.
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344-9. (Pubitemid 351289042)
15. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
17. Wolf FM. Meta-analysis: quantitative methods for research synthesis. Beverly Hills: Sage; 1986.
18. McKeage K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS Drugs. 2009;23:881-97.
19. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother. 2009;9:591-8.
20. Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2:17-32.
21. Almeida QJ, Frank JS, Roy EA, Patla AE, Jog MS. Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease. Mov Disord. 2007;22:1735-42. (Pubitemid 47597596)
22. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699-723. (Pubitemid 47532143)